Markets desk·updated through the day
Markets/EquitiesArticle

Swiss Portfolio Review Highlights Equity Moves and Corporate Updates

A portfolio review of 2026 equity favorites details performance updates, recent transactions, and market developments across multiple Swiss-listed companies.

Helvetic Markets Desk · 2 Nov 2026 · 14:00 · 4 min read
Share
Swiss Portfolio Review Highlights Equity Moves and Corporate Updates
Photo: Jeffrey Beall / Wikimedia Commons, CC BY-SA 4.0

As of October 30, 2026, the portfolio composition of equity favorites holds 6,982 in cash, with a total portfolio value reaching 145,134 and an overall gain of 9.2 percent based on closing prices from that date.

Among the holdings, Amrize N comprises 432 shares with an entry price of 40.66 and a current price of 33.85, representing a current value of 14,623 and a loss of 16.7 percent. Following a disappointing third quarter, the building materials manufacturer lowered its financial targets for the year. Early trading on the results day saw shares drop by nearly 10 percent before recovering to close higher, aided by CEO Jan Jenisch during an analyst conference. While former parent Holcim is geographically diversified, Amrize faces a slowdown in its primary North American market. Since its spin-off, performance has lagged expectations, tempering the prior track record established at Sika and Holcim. However, potential improvements in North American construction and upcoming add-on acquisitions are anticipated.

Lonza N consists of 28 shares with an entry price of 538.35 and a current price of 644.20, valued at 18,038 with a 19.7 percent gain. The Basel-based pharmaceutical supplier convinced participants at its investor day regarding its growth prospects, backed by new medium-term targets viewed as ambitious yet credible. The acquisition of the former Genentech production facility in Vacaville, California, continues to be highlighted under CEO Wolfgang Wienand.

Siegfried N includes 151 shares at an entry price of 72.00 and a current price of 71.80, for a total value of 10,842 and a 0.3 percent loss. A UBS analyst recently lowered the 12-month price target slightly, suggesting that the anticipated recovery in day-to-day business could experience delays and market expectations might be overly high.

Dormakaba N holds 109 shares with an entry price of 62.92 and a current price of 70.00, totaling 7,630 in value with an 11.3 percent gain following a successful start to the new financial year and upcoming medium-term targets at an investor day.

Nestlé N counts 214 shares at an entry price of 78.73 and a current price of 84.70, giving a value of 18,126 and a 7.6 percent gain. The food multinational from Vevey reported a strong third quarter with solid volume growth under CEO Philipp Navratil, comparing favorably with rivals Unilever and Danone.

Partners Group N comprises 16 shares with an entry price of 952.05 and a current price of 640.40, valued at 10,246 with a 32.7 percent decline. Sandoz N holds 191 shares with an entry price of 57.87 and a current price of 82.38, valued at 15,732 with a 42.4 percent gain. SGS N includes 142 shares at an entry price of 90.55 and a current price of 103.60, with a value of 14,711 and a 14.4 percent gain. Sika N consists of 44 shares with an entry price of 158.20 and a current price of 179.10, valued at 7,880 with a 13.2 percent gain. Belimo N holds 8 shares at an entry price of 769.40 and a current price of 779.00, totaling 6,232 with a 1.2 percent gain. Dätwyler I comprises 54 shares with an entry price of 156.13 and a current price of 131.20, valued at 7,085 and a 16.0 percent loss, though a better second semester is expected following rival West Pharma's numbers in the healthcare segment. R&S Group N holds 376 shares with an entry price of 16.59 and a current price of 18.63, totaling 7,005 with a 12.3 percent gain. Data from S&P Global indicate that 19 percent of outstanding shares are targeted by short sellers ahead of the company's investor day led by interim CEO Matthias Weibel.

Earlier portfolio transactions on December 30, 2025, included the sale of 328 UBS N shares at 36.96 francs yielding 12,123, 33 Dätwyler I shares at 163.00 francs yielding 5,379, 20 VAT Group N shares at 385.90 francs yielding 7,718, 23 Comet N shares at 225.00 francs yielding 5,175, 33 Roche GS shares at 328.20 francs yielding 10,831, 24 Sandoz N shares at 57.84 francs yielding 1,388, 254 Adecco N shares at 23.12 francs yielding 5,872, 20 Julius Bär N shares at 62.40 francs yielding 1,248, 531 Medmix N shares at 11.24 francs yielding 5,966, and 2,141 Oerlikon N shares at 3.23 francs yielding 6,915. Purchases on the same date included 420 R&S Group N shares at 15.82 francs totaling 6,644, 15 Nestlé N shares at 78.74 francs totaling 1,181, 3 Sika N shares at 162.80 francs totaling 488, 90 Amrize N shares at 43.57 francs totaling 3,921, 14 Lonza N shares at 537.80 francs totaling 7,520, and 146 SGS N shares at 90.86 francs totaling 13,266.

Source: cash.ch — Top News

This article was produced with AI assistance by the Helvetic Markets markets desk.
Share this story